Jump Financial LLC Buys Shares of 75,108 Scholar Rock Holding Co. (NASDAQ:SRRK)

Jump Financial LLC purchased a new position in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 75,108 shares of the company's stock, valued at approximately $3,246,000. Jump Financial LLC owned 0.08% of Scholar Rock as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of SRRK. Wellington Management Group LLP grew its stake in Scholar Rock by 16.2% during the 3rd quarter. Wellington Management Group LLP now owns 199,777 shares of the company's stock valued at $1,600,000 after purchasing an additional 27,801 shares in the last quarter. Barclays PLC grew its position in shares of Scholar Rock by 103.4% during the third quarter. Barclays PLC now owns 165,449 shares of the company's stock worth $1,324,000 after buying an additional 84,118 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Scholar Rock by 7.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 94,795 shares of the company's stock worth $759,000 after buying an additional 6,269 shares during the last quarter. Geode Capital Management LLC raised its holdings in Scholar Rock by 8.5% in the third quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company's stock valued at $12,361,000 after acquiring an additional 120,489 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Scholar Rock by 17.6% during the 4th quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock valued at $205,013,000 after acquiring an additional 708,817 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company's stock.

Scholar Rock Stock Performance

Shares of NASDAQ:SRRK traded up $1.24 on Wednesday, reaching $32.88. 380,630 shares of the company's stock were exchanged, compared to its average volume of 1,233,994. Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The business's 50-day moving average is $32.99 and its two-hundred day moving average is $35.60. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $3.12 billion, a price-to-earnings ratio of -13.99 and a beta of 0.56.

Analysts Set New Price Targets

Separately, Wedbush reissued an "outperform" rating and issued a $50.00 target price on shares of Scholar Rock in a research report on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $42.67.

Insider Buying and Selling

In other Scholar Rock news, CEO Jay T. Backstrom sold 18,372 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total value of $676,640.76. Following the sale, the chief executive officer now directly owns 311,991 shares of the company's stock, valued at $11,490,628.53. This trade represents a 5.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Edward H. Myles sold 142,292 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $35.62, for a total transaction of $5,068,441.04. Following the transaction, the chief financial officer now directly owns 111,345 shares of the company's stock, valued at approximately $3,966,108.90. This trade represents a 56.10 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 250,231 shares of company stock worth $9,056,086 over the last quarter. 19.20% of the stock is owned by company insiders.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.